Diabetic cardiomyopathy is identified as cardiac dysfunction independently of hypertension and coronary artery disease.The mechanism of diabetic cardiomyopathy is complex,of which energy metabolic dysfunction,oxidative stress,cell apoptosis and microangiopathy play important roles.As a chronic complication of diabetes,microangiopathy can result in abnormal cardiac performance such as cardiac ischemia,hypoxia,cardiac fibrosis and so on.Thus it contributes to the occurrence of hypertrophy and heart failure.So control and amelioration of microangiopathy has potential clinical significance on the prevention and treatment of diabetic cardiomyopathy.Statins is one of the most classic and effective cholesterol-lowering drugs,besides the effect on serum lipid,Statins have certain prevention and cure function for cardiovascular disease.In this paper,we discuss the mechanism of microangiopathy in diabetic cardiomyopathy and statins for prevention of microangiopathy,which provides a new basis for the treatment of diabetic cardiomyopathy.%糖尿病心肌病是独立于高血压和冠状动脉疾病的一类心脏功能异常病变，其发病机制并不十分清楚，糖脂代谢紊乱、氧化应激、细胞凋亡、微血管病变等都在其中发挥着重要作用。作为糖尿病的慢性并发症之一，微血管病变能够引起心肌缺血、缺氧，心肌细胞凋亡，心肌纤维化等心功能障碍，进而导致心肌肥厚和心衰的发生。微血管病变与心肌病变的发生具有直接关系，控制和改善微血管病变有利于糖尿病心肌病的治疗。他汀类药物是目前经典的降血脂药物，而且在降低糖尿病患者的心血管事件发生率方面也起着积极作用。本文就微血管病变在糖尿病心肌病中的作用机制及他汀类药物对微血管病变的防治作用做一概述，为糖尿病心肌病的治疗提供新的依据。
展开▼
